Simtuzumab

Simtuzumab (1 µM; 15 days) reduces contraction heterogeneity, contraction time, diastolic time, and COL1A1 deposition area in LMNA^H222P hiPSC-CMs, without altering contraction amplitude^[1].
Simtuzumab (1-50 μg/mL; 72 h) enhances myofibroblast differentiation in primary IPF human lung fibroblasts at 50 μg/mL, particularly with IL-13 stimulation, and induces mild differentiation in primary normal human lung fibroblasts at the same dose without additional stimuli^[2].
Simtuzumab (50 μg/mL; 7 day) does not reduce or alter collagen 1 synthesis in primary normal or IPF human lung fibroblasts, even with pro-fibrotic stimuli^[2].
Simtuzumab (50 μg/mL; 96 h) increases the invasive migration of primary normal and IPF human lung fibroblasts in a scratch wound assay^[2].
Simtuzumab (50 μg/mL; 26 days, replenished twice weekly) accelerates the outgrowth of primary fibroblasts from mixed normal and IPF human lung explant cells and increases the expression of fibrosis-related genes in these cultures^[2].
Simtuzumab (50 μg/mL; 24 h) increases αSMA and Collagen 3 transcript expression in SSEA4⁺-enriched mesenchymal progenitors from normal human lung samples^[2].
Simtuzumab (50 μg/mL; 10 days, replenished every 3 days) increases LOXL2 and PDGFRA transcript expression and induces mesenchymal-like morphological changes in mixed primary cells from normal and IPF human lung explants^[2].
Simtuzumab inhibits human LOXL2 enzymatic activity, blocks fibroblast activation, and reduces LOXL2-mediated extracellular matrix modifications in in vitro assays^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.